摘要 |
The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>5 </SUP>or R<SUP>6 </SUP>is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH<SUB>2</SUB>, O, S, SO, SO<SUB>2</SUB>, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO<SUB>2</SUB>; m is from 0 to 6; R<SUP>4 </SUP>is OH, -O (keto), NH<SUB>2</SUB>, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO<SUB>2</SUB>. Optionally, R<SUP>5 </SUP>and R<SUP>6</SUP>, together with the N-W bond of formula (I), comprise a macrocyclic ring. |